A phase II and biomarker study (MET111644) of the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Final efficacy, safety, and PD results.

A phase II study to evaluate the safety, pharmacodynamics and efficacy of entinostat in combination with nivolumab plus ipilimumab in patients with renal cell carcinoma previously treated with ...

January 10, 2008 — Year-long treatment with the immunosuppressive drug sirolimus led to shrinkage of angiomyolipoma tumors, with volume reduced by nearly 50%, along with improvement in lung function ...

Perivascular epithelioid cell tumours (PEComas) constitute a rare family of mesenchymal neoplasms defined by distinctive epithelioid and myomelanocytic differentiation. Histologically, they range from ...